In patients with T2DM and DKD with GFR >30 mL/min/1.73 m2 , the combination of SGLT2 inhibitors with another antidiabetic drug, preferably metformin, SHOULD BE CONSIDERED to optimize glycemic control and potential reduction of cardiovascular risk, considering the limitations determined by glomerular filtration. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.